{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:56:52Z","timestamp":1789685812293,"version":"4.0.1"},"reference-count":35,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2022,1,29]]},"DOI":"10.1536\/ihj.21-336","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T22:10:15Z","timestamp":1643407815000},"page":"168-175","source":"Crossref","is-referenced-by-count":10,"title":["Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers"],"prefix":"10.1536","volume":"63","author":[{"given":"Nobutaka","family":"Nagano","sequence":"first","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Muranaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ohwada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemichi","family":"Kouzu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Kamiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Fujito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Nagahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"},{"name":"Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Division of Radiology and Nuclear Medicine, Sapporo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ohkubo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sapporo Nishimaruyama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Hisahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagaaki","family":"Katoh","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Liberal Arts and Science, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Liberal Arts and Science, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 2018; 13: 6.","DOI":"10.1186\/s13023-017-0726-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015; 86: 1036-43.","DOI":"10.1136\/jnnp-2014-308724"},{"key":"3","unstructured":"3. Sekijima Y, Yoshida K, Tokuda T, <i>et al<\/i>. Familial Transthyretin Amyloidosis (January 2012) in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online] Copyright, University of Washington, Seattle 1993-2014. Available at: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1194. Accessed December, 2021."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Concei\u00e7\u00e3o I, Coelho T, Rapezzi C, <i>et al<\/i>. Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression. Amyloid 2019; 26: 103-11.","DOI":"10.1080\/13506129.2019.1627312"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kitaoka H, Izumi C, Izumiya Y, <i>et al<\/i>. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 2020; 84: 1610-71.","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Maurer MS, Bokhari S, Damy T, <i>et al<\/i>. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 2019; 12: e006075.","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail 2019; 6: 1128-39.","DOI":"10.1002\/ehf2.12518"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ericzon BG, Wilczek HE, Larsson M, <i>et al<\/i>. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 2015; 99: 1847-54.","DOI":"10.1097\/TP.0000000000000574"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Suhr OB, Larsson M, Ericzon BG, Wilczek HE, FAPWTR&apos;s investigators. Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP World Transplant Registry. Transplantation 2016; 100: 373-81.","DOI":"10.1097\/TP.0000000000001021"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Okumura K, Yamashita T, Masuda T, <i>et al<\/i>. Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation. Amyloid 2016; 23: 39-45.","DOI":"10.3109\/13506129.2015.1123149"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Maurer MS, Schwartz JH, Gundapaneni B, <i>et al<\/i>. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 1007-16.","DOI":"10.1056\/NEJMoa1805689"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Damy T, Garcia-Pavia P, Hanna M, <i>et al<\/i>. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail 2021; 23: 277-85.","DOI":"10.1002\/ejhf.2027"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Adams D, Gonzalez-Duarte A, O&apos;Riordan WD, <i>et al<\/i>. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21.","DOI":"10.1056\/NEJMoa1716153"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Solomon SD, Adams D, Kristen A, <i>et al<\/i>. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43.","DOI":"10.1161\/CIRCULATIONAHA.118.035831"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gertz M, Adams D, Ando Y, <i>et al<\/i>. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract 2020; 21: 198.","DOI":"10.1186\/s12875-020-01252-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Dorbala S, Ando Y, Bokhari S, <i>et al<\/i>. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2- evidence base and standardized methods of imaging. J Card Fail 2019; 25: e1-e39.","DOI":"10.1016\/j.cardfail.2019.08.001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Dorbala S, Ando Y, Bokhari S, <i>et al<\/i>. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Card Fail 2019; 25: 854-65.","DOI":"10.1016\/j.cardfail.2019.08.002"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Gillmore JD, Maurer MS, Falk RH, <i>et al<\/i>. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404-12.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hanna M, Ruberg FL, Maurer MS, <i>et al<\/i>. Cardiac scintigraphy with technetium-99 m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol 2020; 75: 2851-62.","DOI":"10.1016\/j.jacc.2020.04.022"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nehashi T, Oikawa M, Amami K, <i>et al<\/i>. Sporadic cardiac amyloidosis by amyloidogenic transthyretin V122I variant. Int Heart J 2019; 60: 1441-3.","DOI":"10.1536\/ihj.19-134"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kim HM, Sohn DW, Paeng JC. Prevalence of positive <sup>99m<\/sup>Tc-DPD scintigraphy as an indicator of the prevalence of wild-type transthyretin amyloidosis in the elderly. Int Heart J 2019; 60: 643-7.","DOI":"10.1536\/ihj.18-345"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can <sup>99m<\/sup>Tc- pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant ttr amyloidosis? JACC Cardiovasc Imaging 2017; 10: 713-4.","DOI":"10.1016\/j.jcmg.2016.06.003"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Perugini E, Guidalotti PL, Salvi F, <i>et al<\/i>. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46: 1076-84.","DOI":"10.1016\/j.jacc.2005.05.073"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Azevedo Coutinho MC, Cortez-Dias N, Cantinho G, <i>et al<\/i>. The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease. Amyloid 2020; 27: 174-83.","DOI":"10.1080\/13506129.2020.1744553"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Musumeci MB, Cappelli F, Russo D, <i>et al<\/i>. Low sensitivity of bone scintigraphy in detecting phe64leu mutation-related transthyretin cardiac amyloidosis. JACC Cardiovasc Imaging 2020; 13: 1314-21.","DOI":"10.1016\/j.jcmg.2019.10.015"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Arnold JR, McCann GP. Cardiovascular magnetic resonance: applications and practical considerations for the general cardiologist. Heart 2020; 106: 174-81.","DOI":"10.1136\/heartjnl-2019-314856"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Phelan D, Collier P, Thavendiranathan P, <i>et al<\/i>. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98: 1442-8.","DOI":"10.1136\/heartjnl-2012-302353"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Sperry BW, Vranian MN, Tower-Rader A, <i>et al<\/i>. Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality. JACC Cardiovasc Imaging 2018; 11: 234-42.","DOI":"10.1016\/j.jcmg.2017.06.020"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sawada N, Daimon M, Abe H, <i>et al<\/i>. An autopsy case of cardiac amyloidosis with heterogeneous deposition of amyloid protein: a possible mechanism for relative apical sparing of longitudinal strain. CASE (Phila) 2019; 4: 54-6.","DOI":"10.1016\/j.case.2019.09.009"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Lee GY, Kim HK, Choi JO, <i>et al<\/i>. Visual assessment of relative apical sparing pattern is more useful than quantitative assessment for diagnosing cardiac amyloidosis in borderline or mildly increased left ventricular wall thickness. Circ J 2015; 79: 1575-84.","DOI":"10.1253\/circj.CJ-14-1328"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ueda M, Sekijima Y, Koike H, <i>et al<\/i>. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci 2020; 414: 116813.","DOI":"10.1016\/j.jns.2020.116813"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Grandis M, Obici L, Luigetti M, <i>et al<\/i>. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet J Rare Dis 2020; 15: 348.","DOI":"10.1186\/s13023-020-01633-z"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Concei\u00e7\u00e3o I, Damy T, Romero M, <i>et al<\/i>. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid 2019; 26: 3-9.","DOI":"10.1080\/13506129.2018.1556156"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kitaoka H, Izumi C, Izumiya Y, <i>et al<\/i>. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 2020; 84: 1610-71.","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ezawa N, Katoh N, Oguchi K, Yoshinaga T, Yazaki M, Sekijima Y. Visualization of multiple organ amyloid involvement in systemic amyloidosis using <sup>11<\/sup> C-PiB PET imaging. Eur J Nucl Med Mol Imaging 2018; 45: 452-61.","DOI":"10.1007\/s00259-017-3814-1"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/1\/63_21-336\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:23:18Z","timestamp":1715232198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/1\/63_21-336\/_article"}},"subtitle":["Case Series and Review of the Literature"],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.21-336","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"article-number":"21-336"}}